SINOVAC BIOTECH LTD (SVA)

↓ Download CSV

CIK 0001084201 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated B9
  • Fiscal year ends Dec 31

In fiscal 2025, SINOVAC BIOTECH LTD reported revenue of $386.01M, up 6.8% from the prior year. The company ran a net loss, with a net margin of -51.5% and a gross margin of 67.9%. It held $8.54B in total assets against $2.15B in total liabilities.

Key ratios (FY2025)

67.9%
Gross margin
-127.0%
Operating margin
-51.5%
Net margin
-3.1%
Return on equity
+6.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$386.01M$361.37M$470.17M$1.47B$19.37B$510.62M$246.05M$229.65M$174.35M$72.43M
Cost of Revenue$124.03M$140.69M$146.85M$658.19M$988.92M$67.18M$32.47M$24.72M$20.24M$22.39M
Gross Profit$261.98M$220.69M$323.32M$815.24M$18.38B$443.44M$213.58M$204.93M$154.11M$50.04M
Operating Income-$490.13M-$505.54M-$713.98M-$508.99M$17.62B$215.64M$68.56M$45.32M$45.42M$504.0K
Net Income-$198.84M$40.66M-$120.86M-$59.97M$14.12B$185.18M$65.22M$36.11M$36.70M-$720.0K
EPS (Diluted)$-0.83$1.27$-0.19$0.20$113.44$0.97$0.41$0.34$0.45$-0.01
Total Assets$8.54B$12.34B$13.61B$14.03B$16.76B$1.90B$452.30M$369.78M$299.22M$211.35M
Total Liabilities$2.15B$2.04B$1.97B$1.79B$3.21B$781.20M$100.10M$77.85M$122.08M$81.69M
Shareholders' Equity$6.40B$10.29B$11.64B$12.24B$13.55B$1.13B$352.19M$291.93M$177.14M$129.67M
Cash & Equivalents$488.25M$335.27M$1.12B$3.88B$11.61B$1.04B$152.72M$158.17M$114.42M$62.43M
Operating Cash Flow-$512.18M-$56.89M$138.65M-$798.12M$15.32B$479.31M$39.07M$7.94M$59.76M-$13.90M
Capital Expenditures$48.92M$95.96M$156.16M$313.86M$594.21M$127.49M$10.63M$5.61M$11.91M$12.65M
Shares Outstanding71.86M71.86M71.85M71.76M71.60M113.66M109.69M64.98M57.10M56.95M
Dividends Per Share$55.00